Literature DB >> 24446421

Hilar cholangiocarcinoma is pathologically similar to pancreatic duct adenocarcinoma: suggestions of similar background and development.

Yasuni Nakanuma1, Yasunori Sato.   

Abstract

Routine experiences suggest that cholangiocarcinomas (CCAs) show different clinicopathological behaviors along the biliary tree, and hilar CCA apparently resembles pancreatic duct adenocarcinoma (PDAC). Herein, the backgrounds for these similarities were reviewed. While all cases of PDAC, hilar CCA, intrahepatic CCA (ICCA) and CCA components of combined hepatocellular-cholangiocarcinoma (cHC-CCA) were adenocarcinomas, micropapillary patterns and columnar carcinoma cells were common in PDAC and hilar CCA, and trabecular components and cuboidal carcinoma cells were common in ICCA and CCA components of cHC-CCA. Anterior gradient protein-2 and S100P were frequently expressed in perihilar CCA and PDAC, while neural cell adhesion molecule and luminal epithelial membrane antigen were common in CCA components of c-HC-CCA. Pdx1 and Hes1 were frequently and markedly expressed aberrantly in PDAC and perihilar CCA, although their expression was rare and mild in CCA components in cHC-CCA and ICCA. Hilar CCA showed a similar postoperative prognosis to PDAC but differed from ICCA and cHC-CCA. Taken together, hilar CCA may differ from ICCA and CCA components of cHC-CCA but have a similar development to PDAC. These similarities may be explained by the unique anatomical, embryological and reactive nature of the pancreatobiliary tract. Further studies of these intractable malignancies are warranted.
© 2014 Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Entities:  

Keywords:  Biliary tree; Cholangiocytes; Hilar cholangiocarcinoma; Pancreas; Pancreatic ductal adenocarcinoma

Mesh:

Substances:

Year:  2014        PMID: 24446421     DOI: 10.1002/jhbp.70

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  10 in total

1.  Apigenin inhibits growth and induces apoptosis in human cholangiocarcinoma cells.

Authors:  Pantipa Subhasitanont; Daranee Chokchaichamnankit; Khajeelak Chiablaem; Siriporn Keeratichamroen; Lukana Ngiwsara; N Monique Paricharttanakul; Kriengsak Lirdprapamongkol; Churat Weeraphan; Jisnuson Svasti; Chantragan Srisomsap
Journal:  Oncol Lett       Date:  2017-08-02       Impact factor: 2.967

2.  Over 700 Whipples for Pancreaticobiliary Malignancies: Postoperative Morbidity Is an Additional Negative Prognostic Factor for Distal Bile Duct Cancer.

Authors:  Stefano Andrianello; Giovanni Marchegiani; Giuseppe Malleo; Borislav Chavdarov Rusev; Aldo Scarpa; Deborah Bonamini; Laura Maggino; Claudio Bassi; Roberto Salvia
Journal:  J Gastrointest Surg       Date:  2016-11-23       Impact factor: 3.452

3.  Cancerization of ducts in hilar cholangiocarcinoma.

Authors:  Jae W Lee; Yang Zhang; Tadashi Yoshizawa; Pedram Argani; Laura D Wood; Kiyoko Oshima
Journal:  Virchows Arch       Date:  2022-05-09       Impact factor: 4.535

4.  Prognostic significance of contrast-enhanced CT attenuation value in extrahepatic cholangiocarcinoma.

Authors:  Yoshiki Asayama; Akihiro Nishie; Kousei Ishigami; Yasuhiro Ushijima; Yukihisa Takayama; Daisuke Okamoto; Nobuhiro Fujita; Takao Ohtsuka; Tomoharu Yoshizumi; Shinichi Aishima; Yoshinao Oda; Hiroshi Honda
Journal:  Eur Radiol       Date:  2016-10-17       Impact factor: 5.315

5.  Progenitor cell niches in the human pancreatic duct system and associated pancreatic duct glands: an anatomical and immunophenotyping study.

Authors:  Guido Carpino; Anastasia Renzi; Vincenzo Cardinale; Antonio Franchitto; Paolo Onori; Diletta Overi; Massimo Rossi; Pasquale Bartolomeo Berloco; Domenico Alvaro; Lola M Reid; Eugenio Gaudio
Journal:  J Anat       Date:  2015-11-27       Impact factor: 2.610

6.  EVI1 expression is associated with aggressive behavior in intrahepatic cholangiocarcinoma.

Authors:  Mariko Tanaka; Junji Shibahara; Shumpei Ishikawa; Tetsuo Ushiku; Teppei Morikawa; Aya Shinozaki-Ushiku; Akimasa Hayashi; Kento Misumi; Atsushi Tanaka; Hiroto Katoh; Kei Sakuma; Takashi Kokudo; Yoshinori Inagaki; Junichi Arita; Yoshihiro Sakamoto; Kiyoshi Hasegawa; Masashi Fukayama
Journal:  Virchows Arch       Date:  2018-10-23       Impact factor: 4.064

7.  Adaptor protein XB130 regulates the aggressiveness of cholangiocarcinoma.

Authors:  Pirawan Poosekeaw; Chawalit Pairojkul; Banchob Sripa; Prakasit Sa Ngiamwibool; Sitthichai Iamsaard; Chadamas Sakonsinsiri; Raynoo Thanan; Piti Ungarreevittaya
Journal:  PLoS One       Date:  2021-11-15       Impact factor: 3.240

8.  Germline variants of ATG7 in familial cholangiocarcinoma alter autophagy and p62.

Authors:  Stephanie U Greer; Jiamin Chen; Margret H Ogmundsdottir; Carlos Ayala; Billy T Lau; Richard Glenn C Delacruz; Imelda T Sandoval; Sigrun Kristjansdottir; David A Jones; Derrick S Haslem; Robin Romero; Gail Fulde; John M Bell; Jon G Jonasson; Eirikur Steingrimsson; Hanlee P Ji; Lincoln D Nadauld
Journal:  Sci Rep       Date:  2022-06-20       Impact factor: 4.996

Review 9.  Common features between neoplastic and preneoplastic lesions of the biliary tract and the pancreas.

Authors:  Piera Zaccari; Vincenzo Cardinale; Carola Severi; Federica Pedica; Guido Carpino; Eugenio Gaudio; Claudio Doglioni; Maria Chiara Petrone; Domenico Alvaro; Paolo Giorgio Arcidiacono; Gabriele Capurso
Journal:  World J Gastroenterol       Date:  2019-08-21       Impact factor: 5.742

10.  FOXF1 as an Immunohistochemical Marker of Hilar Cholangiocarcinoma or Metastatic Pancreatic Ductal Adenocarcinoma. Single Institution Experience.

Authors:  Jan Hrudka; Zuzana Prouzová; Katarína Mydlíková; Kristína Jedličková; Michal Holešta; Adam Whitley; Lukáš Havlůj
Journal:  Pathol Oncol Res       Date:  2021-04-20       Impact factor: 3.201

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.